Electrogastrogram - The 3CPM Company

Board Of Directors

3CPM® Company's present board is the core management team necessary to grow and build the Company. The current board (5/5 seats filled) has an impressive range of relevant experiences, which has enhanced its ability to quickly accomplish the business plan’s objectives. The Senior Management - Board of Directors are as follows:

Kenneth L. Koch, MD (Founder): is the founder of the 3CPM® Company, as well as the inventor of the Company’s Electrogastrogram. Dr. Koch is the Head of The Section on Gastroenterology at Wake Forest University. Dr. Koch has been conducting research in numerous areas of gastric motility over the past 20 years (Penn State University), during which time he developed clinical Electrogastrography to its current state of the art. Dr. Koch is a graduate of the University of Iowa College of Medicine and a Board certified gastroenterologist. In addition to his numerous peer review publications, he is an internationally respected leader in the field and participant in many symposia around the world concerning gastric disorders and their diagnosis. He is a member of the GI Advisory Boards for Smartpill Corp, IntraPace Corp and Tranzyme Corp.

Bernie DiDario (Director and former President/CEO): prior to joining 3CPM® Company, was the President and CEO of Maven Labs, Inc., a company specializing in the development of noninvasive devices for treating pain and discomfort. From 1984 to 1990 he was the President of Industrial Fermentation Genetics, a biotech Company which manufactured and sold specialty proteins derived from genetic engineering. The Company was acquired in 1990. From 1982 to 1984 he was the President of California Integrated Diagnostics, a manufacturer of kits for the detection of sexually transmitted diseases. The Company was acquired in 1984 by a larger competitor.

He was also a senior consultant with Arthur D. Little, Inc. and was involved with strategic and marketing assignments with numerous companies in the medical area. He has an undergraduate degree in management from Boston University (1976) and graduate degree in Health Policy and Management from Harvard University (1981).

Wendell W. Jones II  (Chief Financial Officer and Director): was the Chief Financial Officer for Maven Labs, Inc. from 1992 to 1997, where he was responsible for finance, accounting, investor relations, treasury and information systems functions. From 1990 to 1992, he was a consultant to the Chairman of Network Solutions, Inc., a Company that engaged in the exclusive registration of Internet addresses. From 1980 to 1983, he was as senior consultant for Arthur D. Little, Inc. where he focused on technology companies. From 1983 to 1990 he was the CFO of Industrial Fermentation Genetics, Inc. (which successfully completed IPO’s in the US and UK) as well as a director and cofounder. In 1976, he graduated from George Washington University with a degree in accounting. He received a Masters in Business Administration from Washington University’s Olin School of Business in 1978.

Mark Noar, MD (Chairman, Interim CEO and Director): joined the Company’s board in 2001. Dr. Noar is a private practice gastroenterologist, with a large clinic in Towson, MD. He has conducted a number of clinical research projects, including the ability of EGG to screen and predict success with surgical intervention for GERD patients. He has published extensively and is an acknowledged expert in reimbursement matters for private practice. He is an advisor to the pharmaceutical and medical device industries, with a successful history of technology introduction and evaluation. Dr. Noar is a graduate of the Universidad Central Del Este Dominican Republic School of Medicine and also has an MPH from the Tulane University. Since joining the company he has overseen the development and patent of the newer version of the EGG, integrating computer-based interpretation and diagnostics into the field and the latest open architecture Research focused EGG, selected as the exclusive EGG used by the NIH in their sponsored research.

Carlos Babini (Director): joined the Company’s board in 2005. Mr. Babini, a Brazilian national who resides in the USA, has over 25 years of leadership experience in various senior management positions in very competitive sectors of the medical device industry. Mr. Babini has a proven track record of expanding new global markets with expertise in building world class, well-disciplined customer centric teams. Mr. Babini is the former President, International and Executive Vice President of Curon Medical, Inc. and prior to that he has served as Chief Operating Officer for Infomedix Communication, a private company which was sold to Stryker and as the GM & Vice President of Advanced Technology for United States Surgical Corporation, a public company which was sold to Tyco. He is currently Executive Vice President and Chief Sales and Marketing Officer for Vision Sciences, Inc.